Back

Relationship between Lipoprotein(a) and subsequent cardiovascular events in patients with different locations of established cardiovascular disease

31 August 2026 (11:15 - 12:00)
Organised by: Logo
Congress Presentation Part of: Lipids and cardiovascular risk (2) Lipids ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mr Jonathan Ebbers

University Medical Center Utrecht, Utrecht (Netherlands (The))

6 More presentations in this session

Presentation thumbnail
Lipid markers and age differences in atherosclerotic cardiovascular disease risk
Miss H. Su (Leuven, BE)
Abstract Slides Video
Presentation thumbnail
Contemporary paediatric lipid percentiles in 5–14-year-olds: a population-based cross-sectional analysis
Doctor J. Krefting (Munich, DE)
Abstract Slides Video
Presentation thumbnail
Risk-weighted apolipoprotein B in patients hospitalized for acute coronary syndrome: characteristics associated with discordance with measured apolipoprotein B levels.
Mr A. Meseguer Hernandez (Cartagena, ES)
Abstract Slides Video
Presentation thumbnail
Impact of atherogenic lipoproteins and inflammatory markers on silent atherosclerosis
Doctor N. Sandau (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Predicted change in 10-year cardiovascular risk one year after initiation of bempedoic acid-based therapy in the MILOS study
Professor K. Parhofer (Munich, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Lipids and cardiovascular risk (2)

The Event

Event poster

ESC Congress 2026

31 August 2026 11:15 CET
You may be interested in
thumbnail
Congress Presentation
Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction and estimating benefits from novel interventions
28 August 2020
thumbnail
Congress Presentation
Remnant cholesterol increases the risk for recurrent vascular events independent of ldl-cholesterol in patients with clinical manifest vascular disease.
3 September 2019
thumbnail
Congress Presentation
The association between dyslipidaemia treatment and the risk of clinical events in edoxaban-treated patients with atrial fibrillation: insights from the 2-year follow-up of ETNA-AF-Europe
28 August 2022
thumbnail
Congress Presentation
Prognostic values of lipoprotein(a) levels for secondary prevention of acute coronary syndrome among patients who underwent primary percutaneous coronary intervention
1 September 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources